BIND Therapeutics completes PhI trial of first Accurin cancer drug

BIND Therapeutics, called BIND Biosciences until earlier this month, collected positive results in a Phase I trial of its nano-targeted BIND-014 drug candidate to treat solid tumors. The drug is the first of BIND's Accurins--nanoparticles programmed to specifically target diseased tissues while minimizing healthy-cell exposure--to reach the clinical level. In the 28-patient study, BIND-014, which contains the chemotherapy docetaxel, was shown to be generally safe and well-tolerated in patients with a variety of advanced or metastatic cancers. Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…